The CPhI Global Pharma Index, launched at this year's CPhI Worldwide event organized by UBM, is the world’s first ever reputation league table of major pharma industries, scoring the reputations of the major pharma economies across a range of attributes. Germany finished top of the rankings for pharmaceutical quality in both APIs and finished dosage drugs. Germany was also voted by the industry as the best country for both knowledge of its pharma professionals and transparency index – essentially, a rank of countries with the best regulations, business transparency and anti-corruption practices. Highlighting the industry’s confidence, of the 500 pharma companies surveyed in the CPhI Global Pharma Index, nearly 80% of respondents were either ‘confident’ or ‘extremely confident’ (60%) in their business outlook for 2018, and 84% of companies stated they are actively looking for new international partners.
This year's CPhI Worldwide closed its 28th edition with pre-audit figures indicating a record-breaking attendance of over 44,500* and 2,598 exhibitors. Held in Frankfurt, Germany, the world’s largest pharma event saw attendees from 169 countries – 25% of which are CEO or board level.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.